|
December 15, 2009 - 12:00 PM Eastern Lippert/Heilshorn Life Sciences Conference |
| Aradigm Corporation (OTC: ARDM.OB) Igor Gonda, President and Chief Executive Officer www.aradigm.com Snapshot: Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. The company has product candidates addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation. Recent news: In November the first patient was dosed in a Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in adult patients with non-cystic fibrosis bronchiectasis. In September the company presented Phase 2a trial data demonstrating significant antibacterial concentrations and effects in non-cystic fibrosis bronchiectasis patients following administration of its once-daily inhaled liposomal ciprofloxacin. In August Aradigm received Orphan Drug Designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe. |
| Information contained in this webcast is current as of the date and time first presented. |
 |
| Related Events (times are Eastern) | Date/Time  |  |  |
|---|---|---|---|
| Biotech, Healthcare & Pharma Conference Presentation |  | ||
| Biopharma/Healthcare Investor Forum Presentation |  | ||
| Lippert/Heilshorn Life Sciences Conference Presentation | | ||
| Lippert/Heilshorn Life Sciences Virtual Conference | | ||
| Catalyst Financial Resources Life Sciences Conference | | ||
| BIO CEO & Investor Conference - Day One | | ||
| Third Bay Area Drug Delivery Stocks Forum | | ||
| Second Bay Area Drug Delivery Stocks Forum | | ||
| Seventh Bay Area Biotechnology Stocks Forum | | ||
| Sixth Bay Area Biotech Stocks Forum | | ||
| Bay Area Drug Delivery Stocks Forum | | ||
| Second San Diego Biotechnology Forum | |
 |